

North Central Cancer Treatment Group

N0745, Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy
in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma

Status Change Notice – October 7, 2011

NOTICE OF STATUS CHANGE

Effective October 7, 2011, this study will be permanently closed to accrual. This decision was made after a careful review of toxicity data, current accrual rates, and lower than expected time to progression for patients on the combination arm.

If patients are still receiving Bevacizumab the Bevacizumab should be discontinued. Patients may continue to receive Sorafenib using protocol specified doses and under the discretion of the local treating physician. Follow the study calendar and submission requirements for data collection and monitoring.

Please retain this notice with the protocol.